Today's Date: March 29, 2024
Suffolk Kicks off 2024 “Build With Us @ Suffolk” Program in Boston for Trade Partners, Opening Doors for Minority-,   •   Re:wild and Colossal Biosciences team up to leverage revolutionary technology to save critically endangered species on the brink   •   Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors   •   Parkland Corporation Announces the Results of the 2024 Annual General Meeting of Shareholders   •   Amerex Group Unveils Red Carter Swimwear's Revitalized Collection   •   Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures   •   Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment   •   Jamieson Wellness Publishes Inaugural Sustainability Impact Report   •   Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.   •   VIRGIN HOTELS CHAMPIONS INCLUSIVE TRAVEL FOR NEURODIVERSE TRAVELERS   •   Empire State Realty Trust Receives WELL Health-Safety Leadership Award; Becomes Among the First Commercial Office and Multifamil   •   YMCA of the USA Partners With Old Spice To Increase High School Graduation Among Boys And Young Men Of Color Through Mentorship   •   Sypher Secures Strategic Partnership with FAIA to Fuel Growth   •   National University Receives 2024 Military Friendly® Gold Designation   •   Coachella Concerned That People Have Sex, Says AHF   •   Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages   •   Equalpride Partners with TransLash Media for Trans Day of Visibility, Amplifying Voices of Black Trans Femmes in the Arts   •   Visit Visalia Recognizes Autism Awareness Month in April   •   Make-A-Wish and celebrity wish granters announce goal to recruit 1 million people to become "WishMakers"   •   Carnegie Learning Named 2024 SIIA CODiE Award Finalist for Best Educational Game and Best AI Implementation in Ed Tech
Bookmark and Share

Elegen Launches ENFINIA™ DNA, Rapid Long DNA Synthesis to Power the Bioeconomy

SAN CARLOS, Calif. , March 21 /Businesswire/ - Elegen, a leader in DNA innovation, today announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution. Elegen’s ENFINIA™ DNA represents a major advance in the field, offering an unprecedented combination of length, speed, and accuracy to streamline synthetic biology workflows and scale to meet the demands of the growing bioeconomy.

ENFINIA DNA is available today at lengths up to 7,000 base pairs, delivered within seven business days with customer-validated per-base accuracy of approximately 99.999%. This accuracy is 20 times higher than the conventional gene fragments or blocks typically used in synthetic biology today. This means that customers now have access to fast turnaround, long DNA, wherein the molecules are 95% sequence-perfect. Elegen’s current customers are already using ENFINIA DNA for multiple applications without further cloning or manipulation. When even longer DNA is required, Elegen has demonstrated better than a 95% success rate in constructing sequence-perfect DNA plasmids at lengths over 18,000 base pairs by assembling just a few ENFINIA fragments and picking three colonies.

Elegen has already shipped thousands of DNA constructs to dozens of repeat early access customers. The follow-on sales to these customers and increasing rate of new customer adoption validates Elegen’s unique value proposition. Large pharmaceutical organizations, industrial biotech, food, and agriculture companies can now save months in the development of new therapeutics including mRNA vaccines and gene therapies, as well as proteins, microbial strains, and engineered crops. Furthermore, with production in the United States, organizations can maximize speed and mitigate supply chain risk.

“It is encouraging to see companies like Elegen push the boundaries of DNA synthesis,” said Adam Fisher, Principal Scientist at Ensoma. “We are very excited about their innovative approach to solving the supply challenge of high-quality long DNA.”

“Part of Elegen’s vision is to reduce the need for biofoundries at each and every company to assemble and clone DNA. It costs millions of dollars to staff and equip a biofoundry and the expense and the time is often overlooked,” said Marc Unger, PhD, CSO at Elegen. “We enable life sciences companies to develop faster and get more done in the same amount of time, providing an exponential benefit to customers over time.”

ENFINIA DNA is enabled by Elegen’s proprietary cell-free cloning technology that yields near-clonal accuracy without involving cumbersome traditional cloning methods. This, along with a suite of complementary innovations, powers Elegen’s platform.

“Most recent advances in synthetic DNA production resulted from singular innovations,” said Matt Hill, Elegen’s Founder and CEO. “While these specific incremental improvements might lead to improvements in one small aspect of DNA production, singular improvements often lead to trade-offs. We did not see these improvements unlocking synthetic biology in a way that was likely to be transformative. At Elegen, we have developed a portfolio of innovations that already enable us to deliver better speed, length, reliability, accuracy, and to a moderate extent, complexity, for non-clonal DNA, and customers should expect to see us build upon these innovations further in the near future.”

ENFINIA DNA is available now and can be ordered online at elegenbio.com.

About Elegen

Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience in developing novel and scalable approaches in molecular biology, chemistry, and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com.


STORY TAGS: California, Technology, Genetics, Health Technology, Nanotechnology, Biotechnology, General Health, Pharmaceutical, Health, Agriculture, Natural Resources, Product/Service, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News